Monocyte chemoattractant protein-1 and hypertension: An overview
Hipertens. riesgo vasc
; 39(1): 14-23, ene-mar 2022. ilus, tab
Article
in English
| IBECS
| ID: ibc-203947
Responsible library:
ES1.1
Localization: ES15.1 - BNCS
RESUMEN
Background:
The association between hypertension and cardiovascular disease (CVD) has been increasingly studied through early inflammatory biomarkers. The monocyte chemoattractant protein-1 (MCP-1) is the main chemokine implicated in the inflammatory endothelial process, attracting monocytes and macrophages to the atherosclerotic plaque.Methods:
We reviewed the main observational studies that have analyzed serum MCP-1 in patients with hypertension regardless of CVD, relating them to target organ damage (TOD).Results:
As endothelial dysfunction continues and TOD accumulates, MCP-1 has been perpetuated at higher levels. The relationship between this chemokine and the increase in comorbidities, such as chronic kidney disease, dyslipidaemia, diabetes, and coronary artery disease, became clearer from the observational studies. However, patients with such morbidities use medications with potential anti-inflammatory effects.Conclusion:
There is no normal threshold of MCP-1 for the healthy population, nor a uniform curve pattern, due to a balance between genetic factors, age, gender, comorbidities, TOD, and anti-inflammatory effects of drugs. In fact, MCP-1 seems to have a promising role as a tool for further improvement in cardiovascular risk stratification, as prognostic studies have demonstrated an association with fatal and non-fatal cardiovascular outcomes, regardless of other clinical and laboratory predictors.(AU)
Full text:
Available
Collection:
National databases
/
Spain
Database:
IBECS
Main subject:
Cardiovascular Diseases
/
Chemokine CCL2
/
Hypertension
Limits:
Humans
Language:
English
Journal:
Hipertens. riesgo vasc
Year:
2022
Document type:
Article
Institution/Affiliation country:
Universidade Federal do Rio de Janeiro/Brazil